Full List Of Stories
London’s FTSE 250 was up 0. 1% at 22,189. 66 in afternoon trade on Thursday.
London’s FTSE 100 was up 0. 4% at 6,911. 21 in afternoon trade on Thursday, with sentiment underpinned by dovish minutes from the US Federal Reserve.
The Co-operative Group said on Thursday that it will repay £15. 5m in furlough support but will not pay back business rates relief despite reporting a surge in full-year profits.
London stocks were up but off earlier highs by midday on Thursday, after the FTSE 100 hit its best level since the pandemic following dovish minutes from the US Federal Reserve.
Citi upgraded its stance on shares of software company Sage on Thursday to ‘buy’ from ‘neutral’ as it pointed to improving news flow.
Peel Hunt hiked its price target on Carnival on Thursday to 2,100p from 1,850p following the cruise operator’s first-quarter update a day earlier.
Online fashion retailer Asos posted a jump in interim sales and profit on Thursday as it continues to benefit form the closure of non-essential retailers.
John Laing said on Thursday that it is teaming up with Macquarie Capital and retirement homebuilder MCarthy & Stone to create a UK-based platform to invest in retirement accommodation.
London stocks rose in early trade on Thursday after the US Federal Reserve signalled it will keep monetary policy loose.
Sanne said on Thursday that it has raised £79. 5m in a placing to push ahead with its acquisition strategy.
German factory orders rose in February despite ongoing coronavirus restrictions, according to figures released on Thursday by Destatis.
London stocks were set to rise at the open on Thursday after the Federal Reserve signalled it will keep monetary policy loose.
Prof Sarah Gilbert, the scientist who lead the team that created the Oxford/AstraZeneca coronavirus vaccine, is set for a payday of more than £20m as the biotech firm she co-founded prepares to float on the stock market in the US. Gilbert, who became a household name as a result of her work creating Oxford’s Covid-19 vaccine, owns 5. 2% of Vaccitech, a Oxford University spin-out company that owns the biotechnology behind the AstraZeneca vaccine and others for Mers, hepatitis B, the virus that causes shingles, and a range of cancers.